DXRX Diaceutics Plc

TIDMDXRX

RNS Number : 9077Z

Diaceutics PLC

18 May 2023

18 May 2023

Diaceutics PLC

("Diaceutics" or "the Company")

Results of Annual General Meeting

Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharmaceutical industry, is pleased to announce that all resolutions proposed at its Annual General Meeting held earlier today, were duly passed.

The proxy votes received from shareholders in respect of each resolution are set out below and are available on the Company's website www.diaceutics.com

 
 Resolution                                For (excluding              Against            Total      Withheld 
                                        at Chair's discretion)                          votes cast 
                                          Number          %*       Number       %*                   Number of 
                                         of votes                  of votes                            votes 
    -------------------------------  ---------------  ---------  ----------  -------  ------------  ----------- 
     Ordinary resolution 
      to receive and consider 
      the 2022 Financial 
 1    Statements                          60,055,552    100.00%           0    0.00%   60,055,552        Nil 
    -------------------------------  ---------------  ---------  ----------  -------  ------------  ----------- 
     Ordinary resolution 
      to approve the directors' 
 2    remuneration report               51,885,466       89.43%   6,131,086   10.57%   60,055,552     2,039,000 
    -------------------------------  ---------------  ---------  ----------  -------  ------------  ----------- 
     Ordinary resolution 
      to re-elect Peter 
 3    Keeling as a director             59,406,925       98.92%     648,627    1.08%   60,055,552       Nil 
    -------------------------------  ---------------  ---------  ----------  -------  ------------  ----------- 
     Ordinary resolution 
      to re-elect Michael 
 4    Wort as a director                  55,788,593     92.89%   4,266,959    7.11%   60,055,552       Nil 
    -------------------------------  ---------------  ---------  ----------  -------  ------------  ----------- 
     Ordinary resolution 
      to re-appoint Ernst 
 5    & Young as auditors                 60,055,552    100.00%           0    0.00%   60,055,552        Nil 
    -------------------------------  ---------------  ---------  ----------  -------  ------------  ----------- 
     Ordinary resolution 
      to authorise the directors 
      to determine the remuneration 
 6    of the auditors                     60,055,552    100.00%           0    0.00%   60,055,552        Nil 
    -------------------------------  ---------------  ---------  ----------  -------  ------------  ----------- 
     Ordinary resolution 
      to authorise the directors 
 7    to allot shares                     60,055,552    100.00%           0    0.00%   60,055,552        Nil 
    -------------------------------  ---------------  ---------  ----------  -------  ------------  ----------- 
     Special resolution 
      to authorise the directors 
      to disapply pre-emption 
 8    rights                              60,055,202      99.9%         350    0.01%   60,055,552        Nil 
    -------------------------------  ---------------  ---------  ----------  -------  ------------  ----------- 
     Special resolution 
      to authorise the directors 
 9    to purchase own shares              59,976,122    100.00%           0    0.00%   60,055,552      79,430 
    -------------------------------  ---------------  ---------  ----------  -------  ------------  ----------- 
 

*Percentage of votes cast excludes withheld votes

Enquiries:

 
Diaceutics PLC 
Peter Keeling, Chief Executive Officer                       Via Alma PR 
Nick Roberts, Chief Financial Officer 
 
Stifel Nicolaus Europe Limited (Nomad & Broker)      Tel: +44 (0)20 7710 
                                                                    7600 
Ben Maddison, Nick Harland, Nick Adams 
 
Alma PR                                               Tel: +44(0)20 3405 
                                                                    0205 
Caroline Forde, Kieran Breheny, Matthew Young,   diaceutics@almapr.co.uk 
 Kinvara Verdon 
 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharmaceutical and life science companies with solutions and technology for the commercialisation of their precision medicines, enabled by the proprietary DXRX platform.

DXRX is the world's first diagnostic commercialisation platform for precision medicine, utilising a global network of affiliate laboratories to deliver multiple pipelines of real--world healthcare data insights, advisory services and innovative platform enabled solutions.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGGPURWAUPWGUR

(END) Dow Jones Newswires

May 18, 2023 06:46 ET (10:46 GMT)

Diaceutics (LSE:DXRX)
Historical Stock Chart
From Apr 2024 to May 2024

Diaceutics (LSE:DXRX)
Historical Stock Chart
From May 2023 to May 2024